Browsing: Clinical Trials & R&D

Janux prostate cancer data reveals a lower response rate, impacting its clinical trial progress.

Protego amyloidosis drug receives $130M funding to develop a new treatment for light chain amyloidosis, aiming to improve patient outcomes.

Belite Stargardt drug shows promising results in Phase 3 trial, positioning it for potential market approval.

Protego amyloidosis drug development receives $130M funding to target light chain amyloidosis, potentially improving treatment options.

Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous setbacks.

Novo Nordisk GLP-1 drug fails to meet primary endpoints in Alzheimer’s trials, impacting neurodegeneration treatment hopes.

Bayer Asundexian trial results indicate potential for a new class of cardiovascular drugs in stroke prevention.

Novo Nordisk GLP-1 drug fails in Alzheimer’s trials, impacting potential neurodegeneration treatment.

Bayer Asundexian trial results indicate potential for a new cardiovascular drug class, raising hopes after previous clinical setbacks.

Novo Nordisk’s GLP-1 drug semaglutide fails to slow cognitive decline in Alzheimer’s trials.